Eyenovia (EYEN)
(Delayed Data from NSDQ)
$0.45 USD
0.00 (1.00%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $0.45 0.00 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.45 USD
0.00 (1.00%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $0.45 0.00 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Zacks News
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.
Mettler-Toledo (MTD) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Mettler-Toledo's (MTD) third-quarter results are likely to reflect strength across Laboratory and Industrial segments.
CannTrust (CTST) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
by Zacks Equity Research
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
EPAM Systems (EPAM) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
EPAM Systems' (EPAM) third-quarter results are likely to reflect broad-based demand for its digital solutions.
TiVo (TIVO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
TiVo's (TIVO) third-quarter results are likely to reflect higher licensing agreement wins.
Factors to Consider Ahead of Cutera's (CUTR) Q3 Earnings
by Zacks Equity Research
Cutera (CUTR) third-quarter results are likely to reflect benefits from the incremental adoption of truSculpt iD and 3D products.
Expedia Group's (EXPE) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Expedia Group (EXPE) third-quarter results are expected to reflect strength across Core OTA, Vrbo and Egencia. However, weakness in trivago is likely to have impacted its performance negatively.
Factors Setting the Tone for Square's (SQ) Earnings in Q3
by Zacks Equity Research
Square's (SQ) third-quarter results are likely to reflect its strength across sellers.
Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?
by Zacks Equity Research
Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.
Eyenovia Initiates Phase III Study for Mydriasis Candidate
by Zacks Equity Research
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
Eyenovia Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eyenovia has been struggling lately, but the selling pressure may be coming to an end soon.
Eyenovia Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eyenovia has been struggling lately, but the selling pressure may be coming to an end soon.
Eyenovia, Inc. (EYEN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eyenovia, Inc. (EYEN) Sees Hammer Chart Pattern: Time to Buy?